ERBB2 and non-small cell lung carcinoma: Recently, novel, more selective pan-HER-2 TKIs, such as poziotinib, pyrotinib, tarloxotinib and mobocertinib, have been developed with the objective of improving outcomes in patients with NSCLC with HER-2 mutations.